Duchenne muscular dystrophy+1
RecruitingLong-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001
Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001
- Disease:Duchenne muscular dystrophyDuchenne muscular dystrophy gene carrier
- Substances:Delandistrogene Moxeparvovec
Italy- Participants:0–17 years · 18–64 years
- Substances:Delandistrogene Moxeparvovec
- Sponsor:Sarepta Therapeutics Inc.












